Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD20 + status confers therapeutic sensitivity to Rituximab in patients with Follicular Lymphoma.
This statement is based on a regulatory approval from the Health Canada:
RITUXAN (rituximab for injection) is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin’s lymphoma.